Anxiety disorders are linked to physical illness. These physical problems include arthritis, migraine headaches, respiratory disease, allergies, thyroid disease, etc. The new study done by experts have found an association between depression and physical illness. Evidence of a link between anxiety and physical health was made according to information in this new research.
At the MS Trust we strongly object to Multiple Sclerosis – MS being described as a terminal disease, as happened yet again yesterday in relation to the sad death of Gillian March. ‘Terminal’ is defined as “predicted to lead to death, especially slowly” (OED). We are all dying slowly but in fact the vast majority of people with MS will live fulfilling lives to an advanced age.
In another important milestone, Glivec? (imatinib) has received US regulatory approval to help patients with five distinct and potentially life-threatening disorders, representing the first time that a regulatory authority has ever simultaneously approved one targeted medicine for so many disorders. With today’s decision, and in only five years, Glivec has now been approved in the US for seven diseases, including two solid tumors and five blood disorders with molecular targets known to be inhibited by the drug.
AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) has approved SEROQUEL? (quetiapine fumarate) for the treatment of patients with depressive episodes associated with bipolar disorder. SEROQUEL already is approved for the treatment of acute manic episodes associated with bipolar I disorder and for the treatment of schizophrenia. SEROQUEL is now the first and only single medication approved by the FDA to treat both depressive and manic episodes associated with bipolar disorder.
Bristol-Myers Squibb Company (NYSE: BMY) announced that the U.S. Food and Drug Administration (FDA) has granted approval of a new 300 mg single capsule formulation of REYATAZ? (atazanavir sulfate) for the treatment of HIV-1 infection in adults as part of combination therapy. Taken once daily along with ritonavir and food as part of a anti-HIV drug regimen, the REYATAZ 300 mg single capsule formulation can replace two REYATAZ 150 mg capsules for: patients who have previously received anti-HIV medicines, patients who will be receiving tenofovir disoproxil fumarate, and patients who have never taken anti-HIV medicines that require SUSTIVA? (efavirenz) as part of their anti-HIV drug regimen. The REYATAZ single capsule formulation will be available in the United States within seven business days.
A loving, supportive family can be enough to override a genetic vulnerability to depression, new research suggests. Studies have found that people who carry a “short” version of the serotonin transporter gene — known as 5-HTTLPR — tend to be more susceptible to depression than people without this gene variant. But the new findings, published in the journal Biological Psychiatry, show that to be true only of gene carriers who grew up in a stressful home environment. In contrast, the investigators found that young adult gene carriers whose families were warm and supportive had a reduced risk of depression.
This interesting article addresses some of the key issues regarding healthy sleep habits. A careful reading of this material could make a big difference in how you think about healthy sleep habits to children. Healthy sleep habits for children are as significant as they are a necessary for health, proper growth and well-being.
Researchers in the Greene Infectious Disease Laboratory at Columbia University’s Mailman School of Public Health, the Centers for Disease Control and Prevention, and the Caribbean Primate Research Center have discovered a key mechanism by which the Filoviruses, Ebola and Marburg, cause disease. The identification of an amino acid sequence in Filoviruses that results in the rapid depression of immunological response is described in the December 2006 issue of The FASEB Journal. Using this information, researchers can begin to develop new drugs to stop these devastating diseases.
Pilates is the exercise of choice for dancers, gymnasts, and a host of famous Hollywood celebrities, and now it finds itself firmly entrenched in the mainstream. So why is pilates so hot? Pilates incredible popularity can be traced to the fact that it provides its faithful practitioners with benefits that you simply can’t get through traditional aerobics/strength training format.
Anesiva, Inc. (Nasdaq: ANSV) announced today that the U.S. Food and Drug Administration (FDA) granted orphan drug status to product candidate 4975 for the treatment of a painful condition in the foot known as interdigital neuroma in patients who fail conservative treatments, such as foot pads, NSAID’s (non-steroidal anti-inflammatory drugs) and injections of corticosteroids, that would otherwise require removing or chemically destroying the nerve that causes the pain. Orphan drug designation is granted by the FDA to encourage companies to develop products that treat rare diseases and conditions and includes incentives such as market exclusivity for seven years, tax credits on qualified clinical trial expenses and a waiver of the FDA prescription drug user fees.